ANDA 208763, held by Chartwell Rx. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 208763 (Triamcinolone Acetonide), held by Chartwell Rx, was first approved by FDA on Feb 1, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2017 | Original application | Approved | None posted |
| Triamcinolone Acetonide0.025% · cream;topical | Triamcinolone Acetonide | Rx |
| Triamcinolone Acetonide0.1% · cream;topical | Triamcinolone Acetonide | Rx |
| Triamcinolone Acetonide0.5% · cream;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
